Ignite Creation Date:
2025-12-24 @ 7:19 PM
Ignite Modification Date:
2025-12-25 @ 4:58 PM
Study NCT ID:
NCT00695903
Status:
TERMINATED
Last Update Posted:
2018-12-24
First Post:
2008-06-10
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
Sponsor:
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-09-17
Start Date Type:
ACTUAL
Primary Completion Date:
2010-08-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2010-10-01
Completion Date Type:
ACTUAL
First Submit Date:
2008-06-10
First Submit QC Date:
None
Study First Post Date:
2008-06-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2011-08-23
Results First Submit QC Date:
None
Results First Post Date:
2011-12-06
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-12-03
Last Update Post Date:
2018-12-24
Last Update Post Date Type:
ACTUAL